CrossFit athletes are frequently subjected to high-intensity training sessions that demand commensurately robust muscular and cardiovascular endurance capacities. Despite the propensity of research investigating the role of aerobically-associated ergogenic aids, few have elucidated their combination in highly trained athletic populations. PURPOSE: to evaluate the preliminary efficacy of a novel supplement comprising several empirically-supported ingredients and their potential ability to impact the aerobic performance in experienced CrossFit athletes. METHODS: Six experienced CrossFit athletes (3M/3F; aged 41±13y; training 5±1 times/week) ingested 2.0mL daily of a novel supplement proprietary formulation (Flow, Cerus, Vero Bleach, FL) containing Beetroot (Beta Vulgaris), Ashwagandha (Withania Somnifera), Arjuna (Terminalia Arjuna), Rhodiola (Rhodiola Rosea), as well as Cayenne (Capsicum Annuum) for 28 days between a baseline and post-supplementation maximal oxygen consumption (VO2MAX) assessment. Participants were asked not to change their exercise habits and consumed the aforementioned supplement 30 minutes prior to each training session and/or during the morning on rest days. A 4.0mL supplement dose was additionally administered 30 minutes prior to the post-supplementation aerobic capacity assessment. Both the treadmill VO2MAX and test time-to-fatigue (elapsed finish-start time) were analyzed using separate paired-samples t-tests at a significance level of pRESULTS: Although VO2MAX did not significantly increase (p=.146; Hedge’s G=.737), the participants’ treadmill assessment TTE demonstrated a statistically significant improvement (p=.012, Hedge’s G=.726) from pre- to post-supplementation (10.67 to 12.11 minutes [13.55%], respectively). Notably, the 2/6 participants that experienced pre- to post-supplementation VO2MAX decrements tested positive for COVID-19 during their supplementation period. CONCLUSION: The present pilot study showcases the potential of a novel aerobically-associated ergogenic supplement. Nevertheless, future research should more rigorously evaluate these data by employing a randomized, double-blinded, and placebo-controlled design, as well as a larger sample size before any definitive conclusions may be inferred.



To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.